Page last updated: 2024-10-31

nafamostat and Embolism, Pulmonary

nafamostat has been researched along with Embolism, Pulmonary in 1 studies

nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic

Research Excerpts

ExcerptRelevanceReference
"On the first postoperative day, acute pulmonary thromboembolism (PTE) with occlusion of the pulmonary trunk occurred, and the cardiovascular state became unstable."1.33[Postoperative acute pulmonary thromboembolism treated with nafamostat mesilate]. ( Nuriya, E; Tsuda, K; Yamada, K; Yamamoto, K, 2006)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tsuda, K1
Yamada, K1
Yamamoto, K1
Nuriya, E1

Other Studies

1 other study available for nafamostat and Embolism, Pulmonary

ArticleYear
[Postoperative acute pulmonary thromboembolism treated with nafamostat mesilate].
    Masui. The Japanese journal of anesthesiology, 2006, Volume: 55, Issue:5

    Topics: Aged; Anticoagulants; Benzamidines; Female; Gastrectomy; Guanidines; Humans; Postoperative Complicat

2006